145 related articles for article (PubMed ID: 37501554)
1. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Lugano Criteria Versus RECIL and PERCIST as Prognostic Factors in Diffuse Large B-Cell Lymphoma.
Tang P; Cui F; Jiang C; Zhou Y; Su M; Tian R
Clin Nucl Med; 2024 Apr; 49(4):308-311. PubMed ID: 38271234
[TBL] [Abstract][Full Text] [Related]
3. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
5. Interobserver Agreement of Interim and End-of-Treatment
Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
[TBL] [Abstract][Full Text] [Related]
6. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of
Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
[TBL] [Abstract][Full Text] [Related]
8. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Lombion N; Robin P; Tempescul A; LE Roux PY; Schick U; Guillerm G; Ianotto JC; Berthou C; Salaün PY; Abgral R
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):402-409. PubMed ID: 35133099
[TBL] [Abstract][Full Text] [Related]
10. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
[TBL] [Abstract][Full Text] [Related]
11. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.
Eertink JJ; Arens AIJ; Huijbregts JE; Celik F; de Keizer B; Stroobants S; de Jong D; Wiegers SE; Zwezerijnen GJC; Burggraaff CN; Boellaard R; de Vet HCW; Hoekstra OS; Lugtenburg PJ; Chamuleau MED; Zijlstra JM;
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):943-952. PubMed ID: 34476551
[TBL] [Abstract][Full Text] [Related]
12. RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.
Berzaczy D; Haug A; Staber PB; Raderer M; Kiesewetter B; Jaeger U; Kornauth C; Simonitsch-Klupp I; Mayerhoefer ME
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861433
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with
Wu W; Zhao L; Wang Y; Chen P; Yuan X; Miao L; Zhu Y; Mao J; Cai Z; Ji Y; Wang L; Jia T
Curr Probl Cancer; 2024 Feb; 48():101066. PubMed ID: 38364336
[TBL] [Abstract][Full Text] [Related]
15.
Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
[TBL] [Abstract][Full Text] [Related]
16. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
17. Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography.
Wang L; Zhang S; Xin J
Quant Imaging Med Surg; 2023 Oct; 13(10):6789-6800. PubMed ID: 37869355
[TBL] [Abstract][Full Text] [Related]
18. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
Jo JH; Chung HW; Kim SY; Lee MH; So Y
Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]